New HIV Prevention Injection Offers Hope But Faces Cost Protests 💉

News & Articles
1

Summary:

  1. Revolutionary HIV Prevention: The drug Lenacapavir, initially approved for multi-drug resistant HIV treatment, shows 100% efficacy in preventing HIV infections with just a twice-yearly injection, as confirmed by peer-reviewed results released at the AIDS 2024 conference.

  2. Cost Concerns: The current annual cost of Lenacapavir for HIV treatment in the U.S. is $42,250 per patient, whereas oral PrEP options can be as low as $4 a month. This significant cost difference raises accessibility issues.

  3. Call for Affordable Access: Activists in Uganda, South Africa, and Médecins Sans Frontières are pressing Gilead Sciences to license Lenacapavir to the Medicines Patent Pool to allow for affordable generic versions. Gilead has committed to access pricing and is negotiating voluntary licensing to ensure the drug’s availability in high-incidence, resource-limited countries.

Read more on NPR

2 Likes